Holland Capital successfully raises a new private equity fund of EUR 225 million after a swift fundraising period
Amsterdam/Düsseldorf, March 5, 2024 – After a fundraising period of five months, Holland Capital has established its new investment fund, Holland Capital Growth & Buy Out Fund V. There was significant interest from both existing and new investors, leading to the fund being oversubscribed. As a result, a first-and-final closing occurred at the hard cap of EUR 225 million. Investors in this new fund include (international) institutional parties, family offices, and entrepreneurs (many of whom are active in Healthcare and Technology). The fund is classified as an Article 8 fund under the Sustainable Finance Disclosure Regulation (SFDR).
The fund will continue its existing strategy
Holland Capital will deploy the capital for investments in medium-sized Dutch and German companies operating in the Healthcare, Technology, and Agrifood-Tech sectors. This aligns the investment strategy of this fund with its previous funds. With the SFDR Article 8 classification and the related ESG objectives of the fund, Holland Capital reaffirms its ambitions in this regard.
The fund manager aims to realize 15 to 20 platform investments in the coming years with the available capital. Holland Capital benefits from a continuous and robust lead flow in the mentioned sectors. The first planned investments are already in the final stages of ‘due diligence.’
As an active shareholder, Holland Capital adds value by providing not only capital but also knowledge, a network, and hands-on support in the professionalization of the organization and realization of buy-and-build strategies. Over the past 40 years, Holland Capital has supported over 180 entrepreneurs in growing their businesses. Ewout Prins and Hubert Verbeek, managing partners at Holland Capital, state, “We very much look forward to collaborating with entrepreneurs in this fund, creating value by supporting their companies to a next phase.”
Margot Engels, operational partner & CEO at Holland Capital, “We are grateful for the trust of our investors. The overwhelming enthusiasm is a testament to confidence in Holland Capital’s distinctive approach.”
About Holland Capital
For over 40 years, Holland Capital has responsibly and successfully invested in promising Dutch and German SMEs with growth ambitions. The team understands entrepreneurship and aims for an open, sustainable, and professional relationship with the management teams of the invested companies, with the shared goal of achieving growth. Holland Capital has offices in Amsterdam and Düsseldorf. With specialized sector teams, it focuses on the Healthcare, Technology, and recently added Agrifood-Tech sectors. The team is familiar with the dynamics and opportunities in these sectors and has an extensive network.
Following this successful fundraising, Holland Capital’s total assets under management amount to EUR 500 million, and it currently holds 38 companies in its portfolio. For the fund manager, this marks the eleventh and largest fund since the organization’s establishment in 1981.
Sirius Medical announces CE mark for Pintuition: a non-radioactive localization system to improve breast cancer surgery
Sirius Medical announces CE mark for Pintuition: a non-radioactive localization system to improve breast cancer surgery Eindhoven, June 16, 2020 – Sirius Medical, a MedTech startup, announced that it has received CE mark approval for Sirius Pintuition. With its debut...
Sirius Medical ontvangt CE-markering voor Pintuition: een niet radioactief lokalisatiesysteem ter verbetering van borstkankeroperaties
Sirius Medical ontvangt CE-markering voor Pintuition: een niet-radioactief lokalisatiesysteem ter verbetering van borstkankeroperaties Eindhoven, 16 Juni 2020 Sirius Medical, een medtech startup, kondigt aan dat het CE-markering heeft ontvangen voor Sirius...
CytoSMART to donate 100 live-cell imaging systems to assist COVID-19 researchers
CytoSMART to donate 100 live-cell imaging systems to assist COVID-19 researchers Eindhoven, The Netherlands - 22 April 2020, - CytoSMART Technologies is to donate 100 mini live-cell imaging systems to researchers in high containment labs worldwide. Labs working to...
Yenlo benoemd tot Platinum VAR, de hoogste WSO2 Reseller status
Yenlo benoemd tot Platinum VAR, de hoogste WSO2 Reseller statusYenlo is benoemd tot WSO2 Platinum Value-Added Reseller als erkenning voor de behaalde successen en het leveren van de beste opensource integratie- en API-managementoplossingen gebaseerd op het WSO2...
Yenlo Achieves Highest WSO2 Reseller Status as a Platinum VAR
Yenlo Achieves Highest WSO2 Reseller Status as a Platinum VAR Yenlo was named a WSO2 Platinum Value-Added Reseller in recognition of its success in growing global customer adoption and delivering best-in-class open source integration and API management solutions based...
Portfolio company Inno4Life sold to the Swiss company Dec Group
Portfolio company Inno4Life sold to the Swiss company Dec Group Amsterdam, April 16, 2020 - Earlier this month, Inno4Life, a manufacturer of machines for the pharmaceutical industry, was sold to the Swiss Dec Group. Inno4Life's management will remain actively involved...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl